{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:08Z","timestamp":1791849368533,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Africa, Russia, Saudi Arabia, Taiwan, and T\u00fcrkiye.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Medical records (2010\u20132011) of patients (\u2265\u200918\u00a0years) with newly diagnosed MM were analyzed. The primary endpoint was time to next treatment (TTNT). Secondary endpoints included treatment pathways and clinical outcomes stratified by stem cell transplantation (SCT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 1511 patients analyzed (median age: 59.5\u00a0years), 32% had IgG kappa MM and 35.9% had International Staging System stage III disease. Bortezomib- and thalidomide-based chemotherapy regimens were the most common first- and second-line treatments; lenalidomide-based regimens were common in later lines. Median TTNT from initiation of first-line treatment was 39.5\u00a0months. Only 31.7% of patients received SCT at diagnosis, with improved outcomes versus those without SCT (median overall survival: 114.1 vs 85.9\u00a0months; 5-year relapse-free rates after first-line treatment: 58.2% vs 49.3%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Treatment strategies for MM outside Europe and North America align with guideline recommendations. More effective treatments and SCT at treatment initiation are needed. This study can guide future research in these regions utilizing newer treatment options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12185-025-03972-8","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:54:31Z","timestamp":1744732471000},"page":"231-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study"],"prefix":"10.1007","volume":"122","author":[{"given":"Kihyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Verburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Mitina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"1","key":"3972_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","volume":"9","author":"L Naymagon","year":"2016","unstructured":"Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52. https:\/\/doi.org\/10.1186\/s13045-016-0282-1.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3972_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PPO.0000000000000355","volume":"25","author":"R Szalat","year":"2019","unstructured":"Szalat R, Munshi NC. Novel agents in multiple myeloma. Cancer J. 2019;25(1):45\u201353. https:\/\/doi.org\/10.1097\/PPO.0000000000000355.","journal-title":"Cancer J"},{"key":"3972_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174082","author":"D Dima","year":"2022","unstructured":"Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers. 2022;14(17):4082.\u00a0https:\/\/doi.org\/10.3390\/cancers14174082.","journal-title":"Cancers"},{"issue":"14","key":"3972_CR4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJMe1700453","volume":"376","author":"CA Schiffer","year":"2017","unstructured":"Schiffer CA, Zonder JA. Transplantation for myeloma\u2014now or later? N Engl J Med. 2017;376(14):1378\u20139. https:\/\/doi.org\/10.1056\/NEJMe1700453.","journal-title":"N Engl J Med"},{"issue":"6","key":"3972_CR5","first-page":"397","volume":"3","author":"FA Fasola","year":"2012","unstructured":"Fasola FA, Eteng KII, Akinyemi JO. Multiple myeloma: challenges of management in a developing country. J Med Med Sci. 2012;3(6):397\u2013403.","journal-title":"J Med Med Sci"},{"key":"3972_CR6","first-page":"Ch. 9","volume-title":"Update on multiple myeloma","author":"N Ogbonn Collins","year":"2018","unstructured":"Ogbonn Collins N. Management of multiple myeloma in developing countries. In: Khalid Ahmed A-A, editor. Update on multiple myeloma. Rijeka: IntechOpen; 2018. p. Ch. 9."},{"issue":"10","key":"3972_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.clml.2019.06.007","volume":"19","author":"A Chari","year":"2019","unstructured":"Chari A, Parikh K, Ni Q, Abouzaid S. Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide- and\/or bortezomib-containing regimens without stem cell transplant in a real-world setting. Clin Lymphoma Myeloma Leuk. 2019;19(10):645\u201355. https:\/\/doi.org\/10.1016\/j.clml.2019.06.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"3972_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.20452\/pamw.4305","volume":"128","author":"D Coriu","year":"2018","unstructured":"Coriu D, Dytfeld D, Niepel D, Spicka I, Markuljak I, Mihaylov G, et al. Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries. Pol Arch Intern Med. 2018;128(9):500\u201311. https:\/\/doi.org\/10.20452\/pamw.4305.","journal-title":"Pol Arch Intern Med."},{"issue":"3","key":"3972_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.13439","volume":"105","author":"M Mohty","year":"2020","unstructured":"Mohty M, Knauf W, Romanus D, Corman S, Verleger K, Kwon Y, et al. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple myeloma in France, Germany, Italy, and the United Kingdom. Eur J Haematol. 2020;105(3):308\u201325. https:\/\/doi.org\/10.1111\/ejh.13439.","journal-title":"Eur J Haematol"},{"issue":"10","key":"3972_CR10","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","volume":"18","author":"M Mohty","year":"2018","unstructured":"Mohty M, Terpos E, Mateos M-V, Cavo M, Lejniece S, Beksac M, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401\u201319. https:\/\/doi.org\/10.1016\/j.clml.2018.06.018.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"3972_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Hematol. 2016;175(2):252\u201364. https:\/\/doi.org\/10.1111\/bjh.14213.","journal-title":"Br J Hematol"},{"issue":"1","key":"3972_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s12325-020-01546-0","volume":"38","author":"J He","year":"2021","unstructured":"He J, Schmerold L, Van Rampelbergh R, Qiu L, Potluri R, Dasgupta A, et al. Treatment pattern and outcomes in newly diagnosed multiple myeloma patients who did not receive autologous stem cell transplantation: a real-world observational study\u202f: treatment pattern and outcomes in patients with multiple myeloma. Adv Ther. 2021;38(1):640\u201359. https:\/\/doi.org\/10.1007\/s12325-020-01546-0.","journal-title":"Adv Ther"},{"issue":"9","key":"3972_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222522","volume":"14","author":"WN Liu","year":"2019","unstructured":"Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY, et al. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: a nationwide population-based study and a single-institute analysis. PLoS ONE. 2019;14(9): e0222522. https:\/\/doi.org\/10.1371\/journal.pone.0222522.","journal-title":"PLoS ONE"},{"issue":"8","key":"3972_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4(8): e239. https:\/\/doi.org\/10.1038\/bcj.2014.55.","journal-title":"Blood Cancer J"},{"key":"3972_CR15","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.12659\/msm.907588","volume":"24","author":"X Qian","year":"2018","unstructured":"Qian X, Chen H, Xia J, Wang J, Zhou X, Guo H. Real-world clinical outcomes in elderly Chinese patients with multiple myeloma: a single-center experience. Med Sci Monit. 2018;24:5887\u201393. https:\/\/doi.org\/10.12659\/msm.907588.","journal-title":"Med Sci Monit"},{"issue":"3","key":"3972_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hon.2729","volume":"38","author":"NP Sch\u00fctz","year":"2020","unstructured":"Sch\u00fctz NP, Ochoa P, Duarte P, Remaggi G, Yantorno S, Corzo A, et al. Real world outcomes with bortezomib thalidomide dexamethasone and cyclophosphamide bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A retrospective cohort study from Grupo Argentino de Mieloma M\u00faltiple. Hematol Oncol. 2020;38(3):363\u201371. https:\/\/doi.org\/10.1002\/hon.2729.","journal-title":"Hematol Oncol"},{"key":"3972_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010105","author":"K Akizuki","year":"2020","unstructured":"Akizuki K, Matsuoka H, Toyama T, Kamiunten A, Sekine M, Shide K, et al. Real-world data on clinical features, outcomes, and prognostic factors in multiple myeloma from Miyazaki Prefecture, Japan. J Clin Med. 2020;10(1):105. https:\/\/doi.org\/10.3390\/jcm10010105.","journal-title":"J Clin Med"},{"issue":"7","key":"3972_CR18","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","volume":"100","author":"MJ Cejalvo","year":"2021","unstructured":"Cejalvo MJ, Bustamante G, Gonz\u00e1lez E, V\u00e1zquez-\u00c1lvarez J, Garc\u00eda R, Ram\u00edrez-Payer \u00c1, et al. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021;100(7):1769\u201378. https:\/\/doi.org\/10.1007\/s00277-021-04529-5.","journal-title":"Ann Hematol"},{"issue":"4","key":"3972_CR19","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","volume":"98","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Lee JH, Maiolino A, de Queiroz CE, Martinez G, Bittencourt R, et al. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol. 2019;98(4):941\u20139. https:\/\/doi.org\/10.1007\/s00277-019-03602-4.","journal-title":"Ann Hematol"},{"issue":"12","key":"3972_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208507","volume":"13","author":"K Remes","year":"2018","unstructured":"Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Ter\u00e4v\u00e4 V, et al. Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009\u20132013. PLoS ONE. 2018;13(12): e0208507. https:\/\/doi.org\/10.1371\/journal.pone.0208507.","journal-title":"PLoS ONE"},{"key":"3972_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.19.00025","volume":"5","author":"VT de Moraes Hungria","year":"2019","unstructured":"de Moraes Hungria VT, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, et al. Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol. 2019;5:1\u201319. https:\/\/doi.org\/10.1200\/jgo.19.00025.","journal-title":"J Glob Oncol."},{"issue":"1","key":"3972_CR22","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087. https:\/\/doi.org\/10.1186\/s12885-020-07503-y.","journal-title":"BMC Cancer"},{"issue":"11","key":"3972_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443\u20138. https:\/\/doi.org\/10.1038\/leu.2017.138.","journal-title":"Leukemia"},{"key":"3972_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100252","volume":"15","author":"F Nasr","year":"2021","unstructured":"Nasr F, Ghoche AA, Diab S, Nasr L, Ammanouil E, Riachy C, et al. Lebanese real-world experience in treating multiple myeloma: a multicenter retrospective study. Leuk Res Rep. 2021;15: 100252. https:\/\/doi.org\/10.1016\/j.lrr.2021.100252.","journal-title":"Leuk Res Rep"},{"issue":"1","key":"3972_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66\u201376. https:\/\/doi.org\/10.1111\/bjh.14193.","journal-title":"Br J Haematol"},{"issue":"3","key":"3972_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol. 2021;32(3):309\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Ann Oncol"},{"issue":"1","key":"3972_CR27","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","volume":"19","author":"RJP de Magalh\u00e3es Filho","year":"2019","unstructured":"de Magalh\u00e3es Filho RJP, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR, et al. Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries. Clin Lymphoma Myeloma Leuk. 2019;19(1):e43\u201350. https:\/\/doi.org\/10.1016\/j.clml.2018.08.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"3972_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","volume":"96","author":"VT Hungria","year":"2017","unstructured":"Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, Peters L, et al. Observational study of multiple myeloma in Latin America. Ann Hematol. 2017;96(1):65\u201372. https:\/\/doi.org\/10.1007\/s00277-016-2866-9.","journal-title":"Ann Hematol"},{"issue":"3","key":"3972_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clml.2020.11.020","volume":"21","author":"C Vargas-Serafin","year":"2021","unstructured":"Vargas-Serafin C, Acosta-Medina AA, Ordonez-Gonzalez I, Mart\u00ednez-Ba\u00f1os D, Bourlon C. Impact of socioeconomic characteristics and comorbidities on therapy initiation and outcomes of newly diagnosed multiple myeloma: real-world data from a resource-constrained setting. Clin Lymphoma Myeloma Leuk. 2021;21(3):182\u20137. https:\/\/doi.org\/10.1016\/j.clml.2020.11.020.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"S1","key":"3972_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","volume":"97","author":"U Goel","year":"2022","unstructured":"Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(S1):S3\u201325. https:\/\/doi.org\/10.1002\/ajh.26512.","journal-title":"Am J Hematol"},{"issue":"5","key":"3972_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","volume":"21","author":"S Gonzalez-McQuire","year":"2018","unstructured":"Gonzalez-McQuire S, Yong K, Leleu H, Mennini FS, Flinois A, Gazzola C, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21(5):450\u201367. https:\/\/doi.org\/10.1080\/13696998.2017.1421546.","journal-title":"J Med Econ"},{"issue":"6","key":"3972_CR32","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.clml.2018.04.003","volume":"18","author":"R H\u00e1jek","year":"2018","unstructured":"H\u00e1jek R, Jarkovsky J, Maisnar V, Pour L, \u0160pi\u010dka I, Mina\u0159\u00edk J, et al. Real-world outcomes of multiple myeloma: retrospective analysis of the Czech registry of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2018;18(6):e219\u201340. https:\/\/doi.org\/10.1016\/j.clml.2018.04.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"3972_CR33","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/cncr.31305","volume":"124","author":"L Tar\u00edn-Arzaga","year":"2018","unstructured":"Tar\u00edn-Arzaga L, Arredondo-Campos D, Mart\u00ednez-Pacheco V, Mart\u00ednez-Gonz\u00e1lez O, Ram\u00edrez-L\u00f3pez A, G\u00f3mez-De Le\u00f3n A, et al. Impact of the affordability of novel agents in patients with multiple myeloma: real-world data of current clinical practice in Mexico. Cancer. 2018;124(9):1946\u201353. https:\/\/doi.org\/10.1002\/cncr.31305.","journal-title":"Cancer"},{"issue":"6","key":"3972_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12185-024-03754-8","volume":"119","author":"H Shibayama","year":"2024","unstructured":"Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, et al. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016\u20132021). Int J Hematol. 2024;119(6):707\u201321. https:\/\/doi.org\/10.1007\/s12185-024-03754-8.","journal-title":"Int J Hematol"},{"issue":"3","key":"3972_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/bjh.16124","volume":"188","author":"VT de Moraes Hungria","year":"2020","unstructured":"de Moraes Hungria VT, Mart\u00ednez-Ba\u00f1os DM, Pe\u00f1afiel CR, Miguel CE, Vela-Ojeda J, Remaggi G, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008\u20132016. Br J Hematol. 2020;188(3):383\u201393. https:\/\/doi.org\/10.1111\/bjh.16124.","journal-title":"Br J Hematol"},{"key":"3972_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106219","volume":"85","author":"C Weil","year":"2019","unstructured":"Weil C, Gelerstein S, Sharman Moser S, Chodick G, Barit Ben-David N, Shalev V, et al. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan. Leuk Res. 2019;85: 106219. https:\/\/doi.org\/10.1016\/j.leukres.2019.106219.","journal-title":"Leuk Res"}],"updated-by":[{"DOI":"10.1007\/s12185-025-04012-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03972-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:03:01Z","timestamp":1753905781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03972-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3972"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03972-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-025-04012-1","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised for retrospective open access.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-025-04012-1","URL":"https:\/\/doi.org\/10.1007\/s12185-025-04012-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kihyun Kim has received research funding from Janssen, BMS, and Amgen, and served as a consultant for Janssen, BMS, Amgen, Takeda, and LG Chem. Estelle Verburgh has received research funding from MSD and Takeda, received honoraria and speaker\u2019s bureau from Takeda, served in an advisory role for MSD, NovoNordisk, and Takeda, and has unpaid roles in the executive committees of South African Clinical Hematology Society and South African Stem Cell Transplantation Society. Tatiana Mitina has received honoraria and serves as a member on the Board of Directors or advisory committee for Takeda. Wenming Chen has received honoraria from Takeda, Johnson & Johnson, Beigene, Amgen, Sanofi, Antengene, and Novartis. Su-Peng Yeh has received honoraria from Abbvie, Amgen, Janssen, Astellas, Astra Zeneca, Novartis, Sanofi, Roche, Bristol Myers Squibb, and Takeda, and has served in an advisory role for Abbvie, Amgen, Janssen, Astellas, Astex, Novartis, Sanofi, and Takeda. Natalia Schutz has received honoraria, research funding, and serves on the advisory board for Takeda, Amgen, Johnson & Johnson, and Sanofi. Fahad Alsharif has no conflicts of interest. Wee Joo Chng has received honoraria from Takeda, Johnson & Johnson, BMS\/Celgene, Amgen, Abbvie, Sanofi, Pfizer, Antengene, and Novartis, and research funding from Johnson & Johnson, BMS\/Celgene, Novartis, and Aslan. Zhongwen Huang is an employee and shareholder of Takeda Pharmaceuticals. Meral Beksac has served on the advisory board and speakers bureau for Amgen, Janssen, Sanofi, and Takeda, and on the advisory board for Oncopeptides.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}